Posted by Michael Wonder on 28 Apr 2021
Akari Therapeutics receives FDA fast track designation for nomacopan for the treatment of bullous pemphigoid
28 April 2021 - A multicenter Phase 3 trial of nomacopan for the treatment of moderate and severe bullous pemphigoid has been initiated.
Akari Therapeutics today announced that the FDA has granted fast track designation to nomacopan for the treatment of patients with moderate and severe bullous pemphigoid.
